Enhancement of alpha interferon activity against HCV replication in the HCV replicon cell culture model using combination therapy.

被引：0
|
作者：
Korba, B [1 ]
Ciancio, A [1 ]
Rinaudo, J [1 ]
Korba, B [1 ]
Ciancio, A [1 ]
Rinaudo, J [1 ]
机构：
[1] Georgetown Univ, Med Ctr, Rockville, MD USA
来源：
HEPATOLOGY | 2002年 / 36卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
486
引用
收藏
页码：284A / 284A
页数：1
相关论文
共 50 条
  • [1] Enhancement of activity against HCV replication by combination therapy in the HCV replicon model
    Korba, B
    Ciancio, A
    Okuse, C
    Rinaudo, J
    ANTIVIRAL RESEARCH, 2003, 57 (03) : A76 - A76
  • [2] The transcriptorne of HCV replicon expressing cell lines in the presence of alpha interferon
    Hayashi, J
    Stoyanova, R
    Seeger, C
    VIROLOGY, 2005, 335 (02) : 264 - 275
  • [3] Novel interferon alpha variant with improved inhibitory activity against HCV genotype 1 replication compared to IFN alpha-2b therapy, in a subgenomic replicon system
    Escuret, V.
    Durantel, D.
    Martin, A.
    Parent, R.
    Hantz, O.
    Trepo, C.
    Menguy, T.
    Bottius, E.
    Dardy, J.
    Maral, J.
    Escary, J.
    Zoulim, F.
    JOURNAL OF CLINICAL VIROLOGY, 2006, 36 : S109 - S109
  • [4] Amantadine and rimantadine have no significant anti-HCV activity in a replicon cell culture system, both alone and in combination with interferon/ribavirin.
    Lai, VC
    Fang, JW
    Naim, S
    Lau, JY
    Zhong, WD
    HEPATOLOGY, 2001, 34 (04) : 421A - 421A
  • [5] HCV expression inhibits interferon signaling in a cell-based HCV replication model.
    Lin, WY
    Hiasa, Y
    Kamegaya, Y
    Blackard, J
    Zander, C
    Beck, G
    Schmidt, EV
    Chung, RT
    HEPATOLOGY, 2003, 38 (04) : 170A - 170A
  • [6] Gene expression associated with interferon alfa antiviral activity in an HCV replicon cell line
    Zhu, HZ
    Zhao, HS
    Collins, CD
    Eckenrode, SE
    Run, Q
    McIndoe, RA
    Crawford, JM
    Nelson, DR
    She, JX
    Liu, C
    HEPATOLOGY, 2003, 37 (05) : 1180 - 1188
  • [7] Utility of HCV viremia as a predictive factor of sustained response during interferon or combination therapy.
    Castro, FJ
    Esteban, JI
    Sauleda, S
    Viladomiu, L
    Bove, M
    Carbonell, J
    Biosca, S
    Eseban, R
    Guardia, J
    HEPATOLOGY, 1998, 28 (04) : 287A - 287A
  • [8] Amantadine/alpha-interferon combination therapy in HCV chronic hepatitis patients non responders to alpha interferon
    Hurtovà, M
    Liuti, A
    Francioso, S
    Ombres, D
    Angelico, F
    JOURNAL OF HEPATOLOGY, 2000, 32 : 191 - 191
  • [9] A minimum mathematical model for suppression HCV RNA replication in cell culture
    Bezmaternikh, K. D.
    Mishchenko, E. L.
    Likhoshvai, V. A.
    Khlebodarova, T. M.
    Ivanisenko, V. A.
    PROCEEDINGS OF THE FIFTH INTERNATIONAL CONFERENCE ON BIOINFORMATICS OF GENOME REGULATION AND STRUCTURE, VOL 2, 2006, : 109 - +
  • [10] IN VITRO ACTIVITY OF THE COMBINATION OF PEGYLATED INTERFERON-LAMBDA (PEG-IFN-λ) WITH DIRECT-ACTING ANTIVIRALS IN THE HCV REPLICON MODEL
    McPhee, Fiona
    Sheaffer, Amy K.
    Freeman, Jeremy A.
    Chaniewski, Susan
    Levine, Steven
    Chen, Chaoqun
    Voss, Stacey A.
    Lemm, Julie
    Gao, Min
    Majumdar, Antara
    Miller, Dennis M.
    Friborg, Jacques
    HEPATOLOGY, 2010, 52 (04) : 1201A - 1202A
12345